Mirum Pharmaceuticals (MIRM) Cash & Equivalents (2018 - 2026)

Mirum Pharmaceuticals' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $324.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 53.39% year-over-year to $324.9 million; the TTM figure through Mar 2026 stood at $324.9 million (up 53.39% YoY), while the FY2025 annual figure was $296.7 million, up 33.08% from the prior year.
• Cash & Equivalents was $324.9 million for Q1 2026 at Mirum Pharmaceuticals, up from $296.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $324.9 million in Q1 2026 to a low of $49.4 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $233.5 million across 5 years, with a median of $239.9 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 79.4% in 2023, then soared 512.81% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $128.0 million in 2022, then soared by 123.69% to $286.3 million in 2023, then decreased by 22.14% to $222.9 million in 2024, then surged by 33.08% to $296.7 million in 2025, then climbed by 9.51% to $324.9 million in 2026.
• The last three Cash & Equivalents figures came in at $324.9 million (Q1 2026), $296.7 million (Q4 2025), and $282.0 million (Q3 2025), per Business Quant data.